- Filter by subject
- All results (217)
- Risk insights (157)
- Nat Cat risks (18)
- Interviews & profiles (108)
- Emerging risks (121)
- Emerging markets (92)
- Whitepapers & studies (17)
- Business continuity (8)
- Risk insights - Marine (11)
- Risk insights - Property (12)
- Fire risk (6)
- Flood risk (5)
- Environmental risks (10)
- Market Commentaries (6)
- Project risks (10)
- Green issues (8)
- Products (9)
Expert Risk Articles
For knowledge sharing worldwide, features on a variety of risk topics in both the AGCS in-house media and external publications.
“There’s no turning back to the old reality”20 February 2018
Katinka Barysch, German economist and financial commentator, and the Director of Political Affairs for Allianz SE answers questions about world events and if things can ever go back to "normal."
Allianz Risk Barometer 2016 - Top risks in focus: Business interruption14 January 2016
Business interruption (incl. supply chain disruption) ranks as the top peril in the Allianz Risk Barometer 2016 for the fourth year in succession with 38% of responses rating this as one of the three most important risks for companies.
Allianz Risk Barometer 2016 - Changes in risk perception13 January 2016
The risk landscape is changing. Businesses face a wider range of disruptive forces in 2016 and beyond. The effects of globalization, digitalization and technological disruption pose fundamental challenges to many business models.
Entertainment Claims trends09 December 2015
The two most significant business interruption losses are due to a cast member/performer being unable to perform and extra expenses related to other circumstances preventing production, such as property damage.
Property & Engineering Claims trends09 December 2015
The shift of manufacturing to China and South East Asia, increased interdependencies, just-in-time production and diminishing stock are resulting in larger BI and contingent BI claims.
Case study: Business interruption at UCB’s Farchim facility09 December 2015
When an explosion inside the UCB plant in Switzerland completely destroyed a building and interrupted its manufacturing process, the global biopharma manufacturer was left facing a significant loss in income.